Answers are grounded in this paper and cite their sources.
The Massachusetts program designed to detect inborn errors of metabolism and transport in newborn infants has already been described.1 Although such a testing program can lead to the early diagnosis of these disorders and to the prevention of certain complications through early treatment, it is important to consider the costs of screening in relation to the realized and potential benefits.Few reports on the costs of screening for metabolic disorders have been published, and these, with one exception, have considered only the gross costs of laboratory testing for phenylketonuria rather than the cost benefit.2 3 4 The single exception analyzes in detail . . .
No takes yet. Share an insight, caveat, or question.
A 1974 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: